Document |
Document Title |
JP2015534554A |
The compound of formula (I) or a salt thereof is disclosed;(I) (In the formula, R1Is -CH2CH2CF3Is; R2Is -CH2(Cyclopropyl), -CH (CH)3) (Cyclopropyl), or -CH2CH2CH3Is; R3Is H, -CH3Or RxIs; R4Is H or RyIs; as well as Rx, Ry, Ra, Rb b, Rc, Y...
|
JP2015533811A |
Equation (I):(I) [In the formula, R1Is -CH2CH2CF3Is; R2Is -CH2CH2CF3, Or -CH2CH2CH2CF3Is; R3Is -CH2CF3, -CH2CN, -CH2(Cyclopropyl), pyridinyl, chloropyridinyl, or tetrahydropyranyl; ring A is phenyl or pyridinyl; Ra, Rb b, Y, and z are de...
|
JP5820462B2 |
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composi...
|
JP2015199748A |
To provide a novel diazepine compound which blocks an Icurrent or a Kv 1.5 channel strongly and more selectively than other Kchannels.Provided is a diazepine compound represented by a formula (1) or a salt thereof. (Rto Rare each indepen...
|
JP2015193633A |
To provide compounds and compositions comprising the compounds useful in the treatment of cancer.Compounds and compositions comprising the compounds useful in the treatment of cancer are described herein. The compounds and compositions c...
|
JP2015531792A |
Equation (I):(I) [in the formula, a) R1Is H or -CH3And R2Is RyIs; or b) R1Is RxAnd R2Is H; RxAnd RyDiscloses the compounds [disclosed herein] and salts thereof. Also disclosed are methods of using the compound to inhibit Notch receptors ...
|
JP2015529253A |
Equation (I):(I) (In the formula, R1Is -CH2CH2CF3Is; R2Is -CH2CH2CH2F, -CH2CF2CH3, -CH2CH2CF3, -CH2CH (CH)3) CF3, -CH2CH2CF2CH3、Is; R3Is H or -CH3Is; ring A is phenyl or pyridinyl; as well as RX,Ry, Ra, Rb b, Y and z are defined herein...
|
JP2015529252A |
Equation (I):(I) [In the formula, R2Is phenyl, fluorophenyl, chlorophenyl, trifluorophenyl, methylisooxazolyl, or pyridinyl; R3Is H, -CH3, -CH2(Cyclopropyl), pyridinyl, chloropyridinyl, or methoxypyridinyl: and Ra, Rb b, Y and z are defi...
|
JP5782586B2 |
Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especia...
|
JP5781928B2 |
The invention relates to an innovative method for synthesis of cyclic amidines. The synthesis starts from a beta-, gamma- or delta-lactone which is twofold brominated. After esterification of the carboxyl function, the bromine atoms are ...
|
JP5769700B2 |
The present invention provides a novel amino compound that blocks the I Kur current or the Kv1.5 channel potently and more selectively than other K + channels. The present invention relates to an amino compound represented by General For...
|
JP2015145401A |
To provide compounds for medicament to inhibit histone deacetylase.This invention provides a compound such as phenyl hydroxamic acid substituted with a group comprising, for example, oxazepine, diazepine, thiazepine skeletons, pyrimidine...
|
JP5756747B2 |
The present invention relates to hexafluoroisopropanol derivatives having the general formula I to pharmaceutical compositions comprising the same and to the use of these hexafluoroisopropanol derivatives in the treatment of atherosclero...
|
JP5745406B2 |
The invention relates to substituted aminoindanes and analogs thereof of formula I and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders su...
|
JP5741574B2 |
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising thes...
|
JP5734666B2 |
This invention relates to novel compounds of the Formula (I), (I*), (I**), I, Ia, Ib, Ic, Id, Ie, If, Ig, Il1-3, Im1-3, In1-3, or Io1-2, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful...
|
JP5718898B2 |
The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The ...
|
JP2015507622A |
Compounds of formula (I) (where m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a, and R4b are as defined herein). Or its pharmaceutically acceptable salt. Also disclosed are methods of making the compounds and using the compounds for the t...
|
JP5676480B2 |
A compound having a 7-membered nitrogen-containing ring skeleton represented by the formula (I), which is useful for the prevention or treatment of diseases, in which chymase is involved and a pharmaceutical containing the same for the p...
|
JP5671626B2 |
A method of buffering a chemical or biological composition, comprising adding to the composition an effective buffering amount of at least one protonated or un-protonated amine-quaternary ammonium compound having a general formula: where...
|
JP2015028083A |
To provide a compound which regulates pyruvate kinase M2(PKM2).A compound which regulates pyruvate kinase M2(PKM2) and a composition containing the compound are provided. A method of using the compound which regulates PKM2 in a treatment...
|
JP2015013878A |
To provide a method for improving pharmacokinetics of a drug metabolized by cytochrome P450 monooxygenase and a method for inhibiting a retroviral protease, in particular, the human immunodeficiency virus (HIV) protease.Provided is a met...
|
JP2015501788A |
The present invention is useful in methods of treating and alleviating heart, brain, kidney, immune, and reproductive system diseases and disorders resulting from ischemia or post-ischemia reperfusion and any downstream complications ass...
|
JP2015501315A |
The present invention provides a compound having the formula (I): [Chemical formula 1] or a salt, N-oxide or tautomer thereof, wherein A is CH, CF or nitrogen; E is CH, CF. Or nitrogen; R0 is hydrogen or C1-2 alkyl; R1a is CONH2; CO2H; o...
|
JP5654027B2 |
The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable sa...
|
JP5650781B2 |
Pyridine-piperazine-phenyl derivatives (I) or their enantiomers, diastereomers or salts, preferably salts with organic or inorganic acid or base, are new. Pyridin-piperazin-phenyl derivative (I) of formula (R 5>-A-R 4>-B 1>-R 3>-A-D-Y 1>...
|
JP5649672B2 |
Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutical...
|
JP5649577B2 |
The present invention provides an industrially advantageous, simple, and efficient process for producing a key intermediate of a benzo[b][1,4]diazepine-2,4-dione compound, which is a therapeutic medicine for arrhythmia. The present inven...
|
JP5640208B2 |
The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The in...
|
JP5623013B2 |
Compounds of the formula: Wherein R is selected from the group consisting of H, NH2, and NHBoc; and R′ is selected from the group consisting of H, CH2Ph and tBu, optionally de-protected. Such compounds may be conjugated with a suitable...
|
JP5602641B2 |
An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R 1 represents a carboxyl gro...
|
JP5597689B2 |
A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.
|
JP5576120B2 |
A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically...
|
JP5570510B2 |
A chromene compound having a skeleton represented by the following formula (1) and exhibiting double peak characteristic: wherein Z is a group represented by any one of the following formulas: n is an integer of 1 to 3, when n is 2 or 3,...
|
JP2014517298A |
Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids.
|
JP5549592B2 |
|
JP2014129378A |
To provide a variety of chemicals to provide VEGF-RTK-antagonist therapies.Organic compounds having the structural formulas (I) and (II) are provided where the variables have the values described in the specification. Pharmaceutical form...
|
JP5539212B2 |
The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasi...
|
JP5538892B2 |
The present invention relates to diazepane-acetamide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11²-HSD-1) and the use of such compounds for the treatment and prevention o...
|
JP5533649B2 |
To provide a cancer pain therapeutic and/or prophylactic agent which can be administered to a patient for a long period of time from the early stage to the final stage of the cancer pain therapy, instead of conventional non-opioid analge...
|
JP5529202B2 |
Pyridine-piperazine-phenyl derivatives (I) or their enantiomers, diastereomers or salts, preferably salts with organic or inorganic acid or base, are new. Pyridin-piperazin-phenyl derivative (I) of formula (R 5>-A-R 4>-B 1>-R 3>-A-D-Y 1>...
|
JP5503557B2 |
The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which do...
|
JP5503559B2 |
The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which do...
|
JP5503558B2 |
The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which do...
|
JP5481739B2 |
To develop a highly safe measure to treat Alzheimer's disease using a secretase-inhibiting substance, there is provided a compound represented by the following general formula (I) or a salt thereof: wherein A represents a phenyl group or...
|
JP5468900B2 |
The present invention relates to novel aniline derivatives and their use in therapy, in particular their use in the treatment of fungal infections.
|
JP2014508104A |
Compounds of general formula (I), their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroi...
|
JP5424867B2 |
Ring-constrained amino acid surrogates of formula (I) where R1, R2, R3, R4, R5, R6a, R6b, R7, and y are as defined in the specification, methods for synthesizing ring-constrained amino acid surrogates of formula (I), methods of use of ri...
|
JP5415767B2 |
The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to a...
|
JP5415530B2 |
The present invention provides compound of Formula (I): or a stereoisomer, tautomer, salt or solvate thereof, wherein the variables are defined herein. The compounds of formula (I) are inhibitors of Bcl-2 family antiapoptotic proteins, c...
|